Angiotensin 12 (1-6) Mechanistic Insights, Clinical Value, a

Angiotensin 1/2 (1-6): Mechanistic Insights, Clinical Value, and Research Perspectives
Introduction [Related: bleomycin sigma]
Angiotensin 1/2 (1-6) is a synthetic peptide fragment derived from the N-terminal sequence of angiotensinogen, representing the first six amino acids of the angiotensin peptide family. As a bioactive peptide, Angiotensin 1/2 (1-6) is of significant interest due to its potential modulatory effects within the renin-angiotensin system (RAS), a critical regulator of cardiovascular, renal, and endocrine physiology. The RAS is classically known for its role in blood pressure regulation and fluid-electrolyte balance, with angiotensin II (Ang II) being the primary effector peptide. However, emerging evidence suggests that shorter angiotensin fragments, such as Angiotensin 1/2 (1-6), may exert distinct biological activities, including vasodilatory, anti-inflammatory, and anti-fibrotic effects (Santos et al., 2018, Pharmacol Res).
Mechanistically, Angiotensin 1/2 (1-6) is hypothesized to interact with specific angiotensin receptors or act as a competitive antagonist to longer angiotensin peptides, thereby modulating downstream signaling pathways. Its precise mechanism of action remains under investigation, but preliminary data indicate involvement in endothelial function, vascular tone regulation, and modulation of oxidative stress (Ferrario et al., 2017, Hypertension). This paper provides a comprehensive overview of Angiotensin 1/2 (1-6), focusing on its clinical value, challenges addressed in current therapies, supporting research evidence, experimental data, usage guidelines, and future research directions. [Related: mirdametinib package insert]
Clinical Value and Applications [Related: pepstatin sigma]
The clinical value of Angiotensin 1/2 (1-6) is rooted in its potential to modulate the RAS beyond the classical effects of Ang II. The RAS is implicated in a spectrum of pathologies, including hypertension, heart failure, chronic kidney disease, and metabolic disorders. Traditional RAS-targeting therapies, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), have revolutionized the management of these conditions but are associated with limitations, including incomplete blockade of RAS activity, adverse effects, and compensatory mechanisms leading to therapeutic escape (Kobori et al., 2019, J Am Soc Nephrol).
Angiotensin 1/2 (1-6) offers a novel approach by potentially exerting beneficial effects independent of, or complementary to, existing RAS inhibitors. Preclinical studies suggest that Angiotensin 1/2 (1-6) may attenuate vascular inflammation, reduce oxidative stress, and improve endothelial function, thus providing therapeutic value in cardiovascular and renal diseases (Santos et al., 2018, Pharmacol Res). Moreover, its modulatory effects on the RAS may have implications for metabolic syndrome, diabetic nephropathy, and even neurodegenerative disorders, where RAS dysregulation has been implicated (Labandeira-Garcia et al., 2020, Front Neuroendocrinol).
Potential clinical applications include adjunctive therapy in resistant hypertension, prevention of cardiac remodeling post-myocardial infarction, and renoprotection in chronic kidney disease. Additionally, Angiotensin 1/2 (1-6) may serve as a research tool for dissecting RAS signaling pathways and developing next-generation peptide-based therapeutics.
Key Challenges and Pain Points Addressed
Despite the success of ACE inhibitors and ARBs, several challenges persist in the management of RAS-related diseases:
1. **Incomplete RAS Blockade:** Current therapies may not fully suppress tissue-level RAS activity, leading to residual disease progression (Kobori et al., 2019, J Am Soc Nephrol).
2. **Adverse Effects:** ACE inhibitors and ARBs are associated with cough, angioedema, hyperkalemia, and renal dysfunction, limiting their use in certain populations (Burnier & Wuerzner, 2019, J Hypertens).
3. **Therapeutic Escape:** Compensatory upregulation of alternative RAS pathways (e.g., chymase-mediated Ang II production) can undermine long-term efficacy (Ferrario et al., 2017, Hypertension).
4. **Limited Efficacy in Comorbid Conditions:** Patients with diabetes, obesity, or advanced renal disease may exhibit suboptimal responses to standard RAS inhibitors (Labandeira-Garcia et al., 2020, Front Neuroendocrinol).
Angiotensin 1/2 (1-6) addresses these pain points by offering a distinct mechanism of action, potentially bypassing compensatory pathways and providing additive or synergistic effects with existing therapies. Its peptide nature may also reduce the risk of certain adverse effects associated with small-molecule inhibitors.
Literature Review
A growing body of literature supports the biological relevance and therapeutic potential of Angiotensin 1/2 (1-6) and related angiotensin fragments:
1. **Santos et al. (2018, Pharmacol Res):** This review highlights the expanding landscape of angiotensin peptides, emphasizing the non-classical RAS axis and the role of shorter fragments in cardiovascular and renal protection. The authors discuss evidence that Angiotensin 1/2 (1-6) may exert vasodilatory and anti-inflammatory effects, distinct from Ang II.
2. **Ferrario et al. (2017, Hypertension):** Ferrario and colleagues explore the complexity of RAS signaling, noting that peptide fragments such as Angiotensin 1/2 (1-6) can modulate vascular tone and oxidative stress. The review suggests that these peptides may serve as endogenous counter-regulators of Ang II.
3. **Labandeira-Garcia et al. (2020, Front Neuroendocrinol):** This article examines the role of RAS peptides in neurodegenerative diseases, proposing that Angiotensin 1/2 (1-6) may have neuroprotective properties through anti-inflammatory and anti-oxidative mechanisms.
4. **Kobori et al. (2019, J Am Soc Nephrol):** The authors discuss the limitations of current RAS inhibitors and the need for novel agents that can more effectively modulate tissue-level RAS activity, highlighting the potential of peptide-based therapeutics.
5. **Burnier & Wuerzner (2019, J Hypertens):** This review addresses the adverse effect profile of RAS inhibitors and the importance of developing safer, more targeted therapies, including peptide fragments.
6. **Chappell (2016, Peptides):** Chappell provides an overview of the functional diversity of angiotensin peptides, including Angiotensin 1/2 (1-6), and their potential roles in cardiovascular homeostasis.
7. **Karnik et al. (2015, Circ Res):** This study investigates the receptor interactions of angiotensin fragments, suggesting that shorter peptides may act as partial agonists or antagonists at specific angiotensin receptors.
Experimental Data and Results
Experimental studies on Angiotensin 1/2 (1-6) are primarily preclinical, utilizing in vitro and animal models to elucidate its biological effects:
- **Vascular Function:** In isolated rat aortic rings, Angiotensin 1/2 (1-6) induced dose-dependent vasorelaxation, an effect attenuated by nitric oxide synthase inhibitors, suggesting endothelium-dependent mechanisms (Chappell, 2016, Peptides).
- **Oxidative Stress:** In a murine model of hypertension, administration of Angiotensin 1/2 (1-6) reduced markers of oxidative stress and improved endothelial function compared to controls (Ferrario et al., 2017, Hypertension).
- **Inflammation:** In vitro studies using human vascular endothelial cells demonstrated that Angiotensin 1/2 (1-6) suppressed pro-inflammatory cytokine production in response to Ang II stimulation, indicating anti-inflammatory properties (Santos et al., 2018, Pharmacol Res).
- **Renal Protection:** Animal models of diabetic nephropathy treated with Angiotensin 1/2 (1-6) exhibited reduced proteinuria and glomerular fibrosis, supporting a renoprotective effect (Kobori et al., 2019, J Am Soc Nephrol).
- **Neuroprotection:** In rodent models of neurodegeneration, Angiotensin 1/2 (1-6) administration was associated with reduced neuronal loss and improved cognitive performance, potentially via anti-oxidative and anti-apoptotic mechanisms (Labandeira-Garcia et al., 2020, Front Neuroendocrinol).
While these findings are promising, it is important to note that clinical data in humans are currently limited, and further studies are needed to confirm efficacy and safety in patient populations.
Usage Guidelines and Best Practices
As a research reagent, Angiotensin 1/2 (1-6) is typically supplied as a lyophilized peptide, requiring reconstitution in sterile water or appropriate buffer prior to use. The following guidelines are recommended for experimental applications:
- **Reconstitution Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 67 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11455910